The Galilee Research Institute (Migal), in Israel, announced that it has developed an oral vaccine for the new coronavirus that is due to be tested soon, although it will still take a few months to carry out the clinical tests and the regulatory process until approval before it is released on the market.
“AFTER 4 YEARS OF RESEARCH FINANCED BY THE MINISTRY OF SCIENCE AND TECHNOLOGY OF ISRAEL, MIGAL’S RESEARCHERS HAVE DEVELOPED AN EFFECTIVE VACCINE AGAINST THE INFECTIOUS BRONCHITIS VIRUS (IBV) OF THE AVIAN CORONAVIRUS, TO BE ADAPTED SOON AS A HAPPY CONTACTS. -19 “Source: Migal Galilee Research Institute
According to Dr. Chen Katz, Head of Migal’s Molecular Microbiology Laboratory, the new oral vaccine for adults and children could “turn the disease into a very mild cold”. He said that for many people who are inoculated and then infected with COVID-19, “they will potentially not be affected by the disease”.
Commenting on the news, David Zigdon, CEO of MIGAL GALILEE RESEARCH INSTITUTE, said, “Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next 8-10 weeks, and to achieve safety approval in 90 days. This will be an oral vaccine, making it particularly accessible to the general public. We are currently in intensive discussions with potential partners that can help accelerate the in-human trials phase and expedite the completion final product development and regulatory activities.”
Many countries such as the USA, England, Cuba, China, Brazil and others are also working to develop vaccines against COVID-19